Baher Daihom

Dr. Baher Daihom

Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Cairo University, Cairo, Al Qāhirah, Egypt
orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 March 2016 in Drug Development and Industrial Pharmacy
Verified
Journal Article
Closed access
PDF file
AAAlaadin Alayoubi
Alaadin Alayoubi
Baher DaihomBaher Daihom
Baher Daihom
HAHitesh Adhikari
Hitesh Adhikari
SMSanjay R Mishra
Sanjay R Mishra
RHRichard Helms
Richard Helms
HAHassan Almoazen
Hassan Almoazen
Purpose: To develop an oral suspension of clindamycin resin complex for the potential use in pediatrics. Methods: Several types of Ion exchange resins were screened for their binding efficiency with clindamycin. In order to develop a suspension formulation, several thickening agents, surfactants, sweeting and flavoring agents, were evaluated for their influence on the release of clindamycin from resinate. Rheological studies were also conducted to select the optimum amounts of the suspending agents. The release profiles of clindamycin in SGF and SIF were also evaluated from freshly prepared suspension and from suspension formulation after storage for one month at 25°C and 40°C. Clindamycin bitterness threshold was determined based on volunteers’ evaluation, and taste evaluation was conducted in 12 adult volunteers who evaluated the taste of the optimized suspension against clindamycin solution. Results: Among all resins tested, Amberlite IRP 69 showed the highest binding efficiency to clindamycin. Several excipients were selected into the suspension formulation based on no or minimum influence on the release of clindamycin from the resinate complex. Moreover, xanthan gum was selected as the optimal suspending agent for the suspension. Clindamycin release profiles in SGF or SIF showed 90% release within 30 minutes from freshly prepared sample. Clindamycin exhibited good stability profiles at 25°C and 40°Cover one month storage. The mean bitterness threshold of clindamycin was 12.5μg/ml, and taste evaluation study in adults showed sustainable taste improvement for suspension over clindamycin solution. Conclusion: Clindamycin/Resin complexation has shown to be an efficient method to mask the taste of clindamycin and was developed into a suspension formulation that can be used in pediatrics.

15 May 2023 in RSC Advances
Verified
Journal Article
Open access
PDF file
SSSamar A. Salim
Samar A. Salim
NBNoha M. Badawi
Noha M. Badawi
SEShahira H. El-Moslamy
Shahira H. El-Moslamy
EKElbadawy A. Kamoun
Elbadawy A. Kamoun
Baher DaihomBaher Daihom
Baher Daihom
The global state of antibiotic resistance highlights the necessity for new drugs that can treat a wide range of microbial infections. Drug repurposing has several advantages, including lower costs and improved safety compared to developing a new compound. The aim of the current study is to evaluate the repurposed antimicrobial activity of Brimonidine tartrate (BT), a well-known antiglaucoma drug, and to potentiate its antimicrobial effect by using electrospun nanofibrous scaffolds. BT-loaded nanofibers were fabricated in different drug concentrations (1.5, 3, 6, and 9%) via the electrospinning technique using two biopolymers (PCL and PVP). Then, the prepared nanofibers were characterized by SEM, XRD, FTIR, swelling ratio, and in vitro drug release. Afterward, the antimicrobial activities of the prepared nanofibers were investigated in vitro using different methods against several human pathogens and compared to the free BT. The results showed that all nanofibers were prepared successfully with a smooth surface. The diameters of nanofibers were reduced after loading of BT compared to the unloaded ones. In addition, scaffolds showed controlled-drug release profiles that were maintained for more than 7 days. The in vitro antimicrobial assessments revealed good activities for all scaffolds against most of the investigated human pathogens, particularly the one prepared with 9% BT which showed superiority in the antimicrobial effect over other scaffolds. To conclude, our findings proved the capability of nanofibers in loading BT and improving its repurposed antimicrobial efficacy. Therefore, it could be a promising carrier for BT to be used in combating numerous human pathogens.

17 March 2016 in Drug Development and Industrial Pharmacy
Verified
Journal Article
Closed access
PDF file
Baher DaihomBaher Daihom
Baher Daihom
AAAlaadin Alayoubi
Alaadin Alayoubi
DMDejian Ma
Dejian Ma
LWLijia Wang
Lijia Wang
SMSanjay Mishra
Sanjay Mishra
HAHassan Almoazen
Hassan Almoazen
Purpose: To evaluate the physicochemical characteristics of clindamycin HCl in a complex form (resinate) with ion exchange resin (Amberlite IRP69). Methods: Drug-resin complex was prepared by simple aqueous binding method. Drug binding study was carried out at different drug and resin concentrations. Several physicochemical characterization studies were conducted to evaluate the resinate complex. These studies included flow properties, in vitro drug release in SGF and SIF, DSC, TGA, Mass spectroscopy and XPRD evaluations. In addition, stability study of resinate complex was conducted at 25oC and 40oC for up to one month. Results: Clindamycin and Amberlite IRP69 have formed a complex (resinate) and has shown good flow properties, good thermal properties and chemical stability (short term over 4 weeks) at 25oC and 40oC. Clindamycin release profiles from resinate in SGF and SIF has shown immediate release characteristics and release in simulated saliva has shown dependence on water volume. Conclusion: The clindamycin stable complex with ion exchange resin (Amberlite IRP69) has the potential for further development as a compatible pediatric liquid formulation (suspension) or a fast disintegrating tablet.

1 August 2020 in Journal of Drug Delivery Science and Technology
Verified
Journal Article
Closed access
Baher DaihomBaher Daihom
Baher Daihom
EBEhab R. Bendas
Ehab R. Bendas
MMMagdy I. Mohamed
Magdy I. Mohamed
ABAlia A. Badawi
Alia A. Badawi

1 October 2020 in Journal of Drug Delivery Science and Technology
Verified
Journal Article
Closed access
Baher DaihomBaher Daihom
Baher Daihom
EBEhab R. Bendas
Ehab R. Bendas
MMMagdy I. Mohamed
Magdy I. Mohamed
ABAlia A. Badawi
Alia A. Badawi

7 January 2016 in Pharmaceutical Development and Technology
Verified
Journal Article
Closed access
PDF file
AAAlaadin Alayoubi
Alaadin Alayoubi
LHLindsay Haynes
Lindsay Haynes
HPHemlata Patil
Hemlata Patil
Baher DaihomBaher Daihom
Baher Daihom
RHRichard Helms
Richard Helms
Hassan AlmoazenHassan Almoazen
Hassan Almoazen
Objective: To develop a fast dissolving film strip containing epinephrine HCl for the potential treatment of pediatric anaphylaxis. Methods: Four different films have been prepared by solvent casting technique where the percentages of the polymer (Lycoat RS720) were optimized. The polymer percentages were (20%, 25%, 27% and 30%) of the total formulation weighs. The thickness and elastic modulus of the optimized film was evaluated using dynamic mechanical analyzer. Epinephrine content uniformity was assessed using UV at wavelength 280 nm. For the dissolution test, fast dissolving films (FDFs) were evaluated in 500 Simulated Saliva, with 50 rpm. In vivo taste and disintegration evaluation was performed on six healthy volunteers. Results: Films formed by formulations 1, 2 and 3 were too sticky after drying, while formulation 4 that has 30% polymer content formed smooth, transparent, flexible and uniform film, and therefore, it was selected for further testing. The value of elastic modulus was determined at 1.325 MPa. The thickness of the film at different locations was measured at 0.29 mm. Drug content in film was measured at 93% ±10. More than 90% of epinephrine was released from the film within 7.2 min. Bitterness of epinephrine was masked efficiently according to volunteer’s comments with average disintegration time of 20 s. Conclusion: This study presents potential proof for using FDFs as a replacement therapy of epinephrine injections for pediatrics.